National Health (Pharmaceutical Benefits Early Supply) Amendment Instrument 2014 (No. 1) specification under subsection 84AAA(2) (No. PB 25 of 2014) (Cth)

PB 25 of 2014

National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 1) – specification under subsection 84AAA(2)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 21 March 2014

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

Amendment determination – Pharmaceutical Benefits – Early Supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No.1) – specification under subsection 84AAA(2).

(2)      This Instrument may also be cited as PB 25 of 2014.

2          Commencement

This Instrument commences on 1 April 2014.

3          Amendment of PB 30 of 2009

Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) (PB 30 of 2009).

Schedule 1        Amendments

[1]   Schedule 1, entry for Denosumab

substitute:

Denosumab Injection 120 mg in 1.7 mL Injection 1 5 Bone metastases The condition must be due to castration-resistant prostate cancer Bone metastases The condition must be due to breast cancer

[2]   Schedule 1, entry for Flutamide

omit:

Tablet 250mg, 30 Oral 3 5

[3]   Schedule 1, after entry for Glyceryl trinitrate in the form Transdermal patch 120 mg

insert:

Glycopyrronium Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) Inhalation by mouth 30 5